Influence of Intravitreal Anti-vascular Endothelial Growth Factor Administration on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 主要终点
- visual acuity
研究概览
简要总结
Purpose:
To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on vitreomacular interface- and retinal morphology in eyes with neovascular age-related macular degeneration (AMD) and to identify morphological markers potentially influencing disease prognosis.
Methods:
43 patients (51 eyes) with treatment naïve neovascular AMD subsequently treated with Bevacizumab 1.25mg (in 0.05ml of solution) were monitored until month 12 of follow-up. Following a loading dose of 3 monthly intravitreal anti-VEGF injections, patients were treated as-needed [pro re nata (PRN)]. Functional and morphological changes were assessed using Spectral Domain Optical Coherence Tomography (SD-OCT).
详细描述
This retrospective study included 43 treatment-naive patients (51 eyes) with neovascular AMD over the course of 12 months. Patients were treated with a loading dose of 3 initial monthly anti-VEGF injections (Bevacizumab 1.25mg in 0.05ml of solution-Avastin®) and were followed monthly until year 1. Re-treatment was performed if needed (pro re nata-PRN) as previously reported.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 66 Years 至 98 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of treatment-naive neovascular AMD
排除标准
- •any treatment with other anti-VEGF agents than Bevacizumab in the follow-up period
- •any other diseases leading to macular edema
- •prior vitrectomy
- •retinal or corneal laser surgery
- •high myopia (>6dpt)
- •preceding eye trauma
结局指标
主要结局
visual acuity
时间窗: 12 months
visual acuity testing was performed
次要结局
未报告次要终点
研究者
Dr. Clara Wernigg
Dr.
Hospital Hietzing